- Home
- ROIV vs AKAM Comparison
ROIV vs AKAM Comparison
Compare ROIV & AKAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | AKAM |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 17.3B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ROIV | AKAM |
|---|---|---|
| Price | $29.34 | $162.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | $28.94 | ★ $107.87 |
| AVG Volume (30 Days) | 4.4M | ★ 5.3M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | $29,053,000.00 | ★ $2,502,996,000.00 |
| Revenue This Year | N/A | $8.53 |
| Revenue Next Year | $744.61 | $7.09 |
| P/E Ratio | ★ N/A | $210.05 |
| Revenue Growth | N/A | ★ 6.96 |
| 52 Week Low | $10.58 | $69.79 |
| 52 Week High | $30.33 | $156.32 |
Technical Indicators
Market Signals| Indicator | ROIV | AKAM |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 80.07 |
| Support Level | $27.00 | $88.67 |
| Resistance Level | $30.26 | N/A |
| Average True Range (ATR) | 0.87 | 7.04 |
| MACD | 0.09 | 6.83 |
| Stochastic Oscillator | 85.95 | 97.73 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.